



Novartis India Limited
Registered Office:
Inspire BKC
Part of 601 & 701
Bandra Kurla Complex
Bandra (East)
Mumbai – 400 051
Maharashtra, India
Tel +91 22 50243000
Fax +91 22 50243010
Email: india.investors@novartis.com
CIN No. L24200MH1947PLC006104
Website: www.novartis.in

March 06, 2023

The Secretary
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001
Scrip Code - 500672

Dear Sir/ Madam,

Sub.: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The Ministry of Health and Family Welfare, Government of India, has released the revised National List of Essential Medicines (NLEM), 2022. The revised list of NLEM may affect 9 (Nine) brands being marketed by the Company. These brands are majorly in the areas of Oncology and Neurology. We are yet to receive Notifications of some brands.

It is likely that such inclusion in NLEM may have some impact on Sales which cannot be completely assessed at this stage. However, the Company is constantly looking at ways to best meet the medical needs of patients in India, while strengthening the Company's competitiveness.

You are requested to take the above information on record.

Thanking you.

Yours Sincerely,

For **Novartis India Limited**

Malpani Nikhil

Digitally signed by Malpani Nikhil
DN: dc=com, dc=novartis, ou=people,
ou=GR, serialNumber=3079238,
cn=Malpani Nikhil
Date: 2023.03.06 16:11:59 +05'30'

Nikhil Malpani
Company Secretary and Compliance Officer